ADAMDEC1

Across TCGA pan-cancer cohorts, ADAMDEC1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMDEC1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ADAMDEC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAMDEC1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where ADAMDEC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.959	0.653	.010	14	view →
LUAD	DFS	Tertile	II,III,IV	0.902	0.343	.006	13	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	7	view →
HNSC	DFS	Tertile	III,IV	0.857	0.505	.025	3	view →
CCRCC	DFS	Median	All	0.602	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAMDEC1–LSCC (DFS)

Open the LSCC breakdown →